Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.

Background And Aim: The biosimilar of infliximab (CT-P13) has been approved for the same indications held by the infliximab reference product (Remicade); however, there are few clinical data on switching in inflammatory bowel disease (IBD). The aim of this study was to assess the efficacy, safety, bioavailability profile and factors associated with relapse after switching to biosimilar infliximab in IBD patients in clinical remission.

Material And Method: Observational study with IBD patients treated with Remicade for at least 6 months and in clinical remission for at least 3 months who switched to infliximab biosimilar.